
FDA approved Novartis’ secukinumab (Cosentyx) 150 mg for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate a taper. In the Phase 3 REPLENISH trial, secukinumab doubled sustained remission rates.
Sciex’s latest additions to its biopharma portfolio helps to optimize workflow for better analytics in the lab.
Sciex’s latest additions to its biopharma portfolio help to optimize workflow for better analytics in the lab.
According to the company, these products have been optimized for maximal sensitivity, accuracy, and efficiency for scientists using challenging workflows in critical fields without sacrificing robustness or ease of use.
Recent additions to the Sciex biopharma portfolio include:
The company showcased these innovations at ASMS 2018 on June 3–7, 2018 in San Diego, CA.
Source:






